þ PCa cells express higher mRNA levels of several 'stemness' genes including Oct-3/4, Bmi, b-catenin, and SMO. Third, CD44
þ PCa cells can generate CD44 À cells in vitro and in vivo. Fourth, CD44
þ PCa cells, which are AR
Introduction
Human prostatic glands consist of two major epithelial cell types: basal and secretory (luminal). Basal cells express cytokeratin 5 (CK5), CK14, Bcl-2 (McDonnell et al., 1992) , Her-2/neu (Reiter and Sawyers, 2001 ), p63 (Signoretti et al., 2000) , and CD44 (Liu et al., 1997) , whereas differentiated luminal cells express CK8, CK18, AR (androgen receptor), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), CD57, and 15-lipoxygenase 2 (Tang et al., 2002; Bhatia et al., 2005) . The basal cell compartment is thought to contain stem/ progenitor cells as >80% of the proliferating cells are localized in the basal layer (Bonkhoff et al., 1994) . Furthermore, molecules known to play an important role in maintaining stem/progenitor cell proliferation (e.g. p63), survival (e.g. Bcl-2), and detoxification (e.g. GST-p), all localize preferentially in the basal cell compartment. That the adult human prostate contains stem cells (SCs) is also supported by the observation that a small number of cells within the prostate possess tremendous proliferative capacity and can form glandular-like structures in reconstituted systems (Hudson et al., 2000) . Several populations of putative human prostate stem/progenitor cells have been reported, which include CK5 and CK18 double-positive (CK5 þ /CK18 þ ) intermediate cells (van Leenders et al., 2000; Wang et al., 2001; Tran et al., 2002; Garraway et al., 2003; Bhatia et al., 2005) , the side population (SP) cells (Bhatt et al., 2003) , and small populations of cells that preferentially express cell surface molecules CD44 (Liu et al., 1997) , a2b1 (Collins et al., 2001) , or CD133 (Richardson et al., 2004) .
CD44, which is spliced into many isoforms, is an adhesion molecule with multiple signaling functions (Ponta et al., 2003) . In the normal prostate, CD44 is expressed in most basal cells. In prostate cancer (PCa), CD44 expression varies in different studies. One study of 109 cases reports a complete lack of membranous expression of all CD44 isoforms in 93-98% of primary PCa examined (Kallakury et al., 1996) . However, another study of 74 PCa lesions reports moderate to high levels of CD44 expression in 60% of primary tumors with B14% of metastases expressing low levels of CD44 (Nagabhushan et al., 1996) . Yet another study reported significantly reduced CD44 expression in all 94 primary neoplastic foci and 48 metastases (De Marzo et al., 1998) . The relationship between CD44 expression and tumor grade is also uncertain -one study shows a strong correlation between Gleason grade of the tumor and loss of CD44 expression (De Marzo et al., 1998) , whereas another reports no correlation (Paradis et al., 1998) . Furthermore, although CD44 expression is reported to be reduced in metastases (Nagabhushan et al., 1996; De Marzo et al., 1998; Noordzij et al., 1999) , the CD44
þ PCa cells are found to predominate in two visceral metastases (Liu et al., 1999) . Similar to expression studies, the potential role of CD44 in PCa development and metastases is controversial -although some studies show a tumor-suppressive function of CD44 in overexpression experiments (Gao et al., 1997 (Gao et al., , 1998 , many other studies implicate CD44 in PCa cell proliferation, adhesion, migration, and invasion in vitro as well as in metastatic dissemination in vivo (Lokeshwar et al., 1995; Paradis et al., 1998; Liu et al., 1999; Draffin et al., 2004; Omara-Opyene et al., 2004) . Many studies mentioned above utilize either human tissues to carry out correlative immunohistochemistry (IHC) or bulk-cultured PCa cells to carry out overexpression experiments and the key experiment of using purified CD44 þ and CD44
À cells from the same culture or tumor to compare their potentially different biological and tumorigenic properties has not yet been done. Therefore, it is not known whether the minor subset of CD44 þ PCa cells in both primary and metastatic lesions are intrinsically different from bulk CD44 À PCa cells. We address this issue in this study using mainly xenograft prostate tumors as they provide a renewable source of genetically stable tumor materials (Reiter and Sawyers, 2001) . Our results reveal that the CD44 þ PCa cells are inherently more tumorigenic and metastatic than the isogenic CD44 À PCa cells. Importantly, highly purified CD44
þ PCa cells possess many intrinsic traits of tumor progenitors.
Results

CD44 expression in PCa cells or PCa cell-derived spheres correlates with tumor cell malignancy
To determine whether CD44 marks more tumorigenic PCa cells, we first examined its expression, using an anti-CD44 antibody that recognizes both standard and all CD44 isoforms, in PCa cell lines LNCaP, Du145, and PC3, which show increasing tumorigenicity and malignancy (van Bokhoven et al., 2003) . We observed that although CD44 expression was detected in 100% of PC3 cells, it was expressed in B28% of Du145 cells and undetectable in LNCaP cells or LNCaP spheres ( Figure S1 ; Table S1 ). PPC-1 cells, a PC3 derivative, also showed 100% CD44 expression ( Figure S1 ; Table S1 ). In contrast, two low-tumorigenic, nonmetastatic cell lines recently established in our lab, the NHP6-hTERT/T (normal human prostate 6 (NHP6) cells immortalized with hTERT and SV40 large T) and NHP6-DNp53/T (NHP6 cells immortalized with dominant negative p53 and large T), showed CD44 expression in only 2-3% of the cells (Table S1 ). These results suggest that CD44 expression in cultured PCa cells seems to correlate with cancer cell tumorigenicity.
To determine whether this relationship may be unique to PCa cells, we also examined CD44 expression in multiple other cancer cell lines including those of the breast, colon, bladder, cervix, and ovary as well as glioma and melanoma cells. Interestingly, in most cases, we found a positive correlation between CD44 expression and tumor cell malignancy ( Figure S1 ; Table S1 ).
Highly purified CD44
þ PCa cells possess higher proliferative capacity and clonogenicity than the CD44 À PCa cells Next, we purified CD44 þ and CD44 À cells from several PCa cell cultures or xenografts and compared their clonal and clonogenic properties. We first purified CD44 þ cells from cultured NHP6-hTERT/T cells, which expressed CD44 in only B2% of the cells ( Figure  1Aa ; Table S1 ). The purity of the CD44 þ and CD44 À cell populations was generally X98% as revealed by both post-sort immunostaining ( Figure S2A ) and flow analysis (not shown). As shown in Figure 1A (b-d), the CD44 þ NHP6-hTERT/T cells proliferated more than the CD44 À cells. The CD44 þ NHP6-hTERT/T cells also formed significantly more colonies on soft agar than the CD44 À cells (Figure 1Ae -h), and many cells in the spheres derived from the CD44 þ NHP6-hTERT/T cells were actively dividing (Figure 1Ag) . No difference in adhesion and viability was observed between the CD44 þ and CD44
À NHP6-hTERT/T cells. For example, most CD44 À NHP6-hTERT/T cells plated in clonal analyses were adherent and alive but failed to form sizable clones (Figure 1Ac ). Similarly, most CD44 À NHP6-hTERT/T cells plated in clonogenic assays were alive but failed to establish distinct spheres (Figure 1Af ).
We similarly purified CD44 þ and CD44 À cells from the NHP6-DNp53/T cells, which expressed CD44 in 1-3% of the cells (Figure 1Ba ; Table S1 ). Clonal analyses indicated that the CD44 þ NHP6-DNp53/T cells formed larger and more clones than the CD44 À cells (Figure 1Bb -e), resulting in more cells at the end of the assays (Figure 1Bf) . Furthermore, the CD44 þ NHP6-DNp53/T cells formed more and bigger colonies than the CD44 À cells when plated on soft agar ( Figure  1Bg ). Next, we purified CD44 þ and CD44 À Du145 cells from xenograft tumors. As shown in Figure 1Ca -c, purified CD44
þ Du145 cells proliferated significantly more than the CD44 À Du145 cells during the 7-day assay period. Also, the CD44 þ Du145 cells showed higher clonogenicity on soft agar (Figure 1Cd ). Finally, we performed similar experiments in PC3 cells. Cultured PC3 (Table S1) hi and CD44 lo PC3 cells purified using the Macs system were plated in triplicate at 50 000 cells/T25. Cells were harvested at the end of 1 week to determine the cell number. Data represent the mean7s.d. *Po0.01.
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þ PCa cells possess higher tumorigenicity than the CD44 À PCa cells To determine whether the CD44 þ PCa cells might be more tumorigenic than the CD44 À counterparts, we carried out tumor development experiments first using CD44 þ and CD44 À cells acutely purified from the NHP6-DNp53/T xenograft tumors. As shown in Table 1 , when 1000 cells were injected subcutaneously (s.c.) into NOD/SCID mice, the CD44 þ NHP6-DNp53/ T cells gave rise to more tumors with shorter latencies than the CD44 À cells. However, when 10 000 respective cells were injected, no difference in tumor incidence was observed between the two populations although the CD44 À cells initiated tumors with longer latency periods (Table 1) .
We then carried out similar experiments using isogenic cells purified from the Du145 xenograft tumors. The unsorted Du145 cells showed a cell numberdependent increase in tumor incidence and decrease in the median latency period (Table 1 ). The purified CD44 þ Du145 cells showed higher tumorigenicity than the corresponding CD44 À Du145 cells in that the former had higher tumor incidence with shorter latency intervals ( Table 1 ). For example, with 100 and 1000 CD44
þ Du145 cells injected, we observed B60% (5/8) tumor incidence (Table 1 ). By contrast, with 100 CD44 À Du145 cells injected, we observed a tumor incidence of B13% (1/8) ( Table 1 ) and with 1000 CD44
À Du145 cells injected, we observed no tumor development within 6 months (Table 1) . Also, it took the CD44 À cells longer time to initiate a tumor than the CD44 þ tumor cells (Table 1) . However, with 10 000 CD44 À Du145 cells injected, tumors did develop (3/8) with long latencies (Table 1) .
Next, we utilized two well-characterized human PCa xenograft models, that is, LAPC-4 and LAPC-9 (Reiter and Sawyers, 2001) , to further study whether CD44 expression is associated with higher tumorigenicity. The LAPC-4 tumor was derived from a lymph node metastasis whereas the LAPC-9 tumor from a bony metastasis and both tumors are AR positive. When purified LAPC-4 cells were plated in IMDM medium supplemented with 20% FBS (Figure 2Aa ), or LAPC-9 tumor cells freshly purified from the xenograft tumors were plated on a fibroblast feeder layer in the same medium ( Figure 2Ab ), both cell types formed prominent spheres indicative of the presence of stem-like tumor cells (Patrawala et al., 2005) . On average, B0.7 and 0.2% of the LAPC-4 and LAPC-9 cells, respectively, had sphere-forming abilities. The spheres contained tumorigenic cells in that 10 LAPC-4 spheres injected into a NOD/SCID mouse initiated three distinct tumors (not shown). Cells in the spheres were all positive for Ber-EP4 (Figure 2Ac ), a human epithelia-specific surface marker (Latza et al., 1990) , as well as for CK18 (Figure 2Ad ). Most BrdU þ , proliferating cells were localized in the peripheral regions (Figure 2Ad ), whereas AR þ , differentiated LAPC-4 cells localized exclusively at the outermost layer of the spheres (Figure 2Ae ). Staining of multiple spheres revealed a small percentage of CD44 þ cells mostly around the peripheral areas of the spheres (Figure 2Af ). Co-staining of CD44 and AR did not reveal any double-positive cells in serial cryosections of 20 spheres analysed (not shown; also see Figure 6b ). Overall, B4 CD44 þ cells were observed on each 8-mm section of LAPC-4 sphere and B0.2% of total cells in the spheres were CD44 þ ( Figure 2Ag ). The CD44 þ cells were detected in the LAPC-4 tumors at a frequency of B0.1% (Figure 2Ba ; also see Table 3 ). Interestingly, the LAPC-9 tumor, derived from a bony metastasis, contained much higher percentages (i.e. B14-20%) of CD44 þ cells (Figure 2Bb ). Figure S2B ). As shown in Figure 2C , purified CD44 þ LAPC4 (a) and LAPC-9 (b) cells showed much higher sphere-forming abilities than the CD44 À counterparts. When injected s.c. into the NOD/SCID mice, the unsorted LAPC-4 tumor cells showed a cell numberdependent increase in tumorigenicity with a corresponding decrease in latency (Table 1) . When purified LAPC-4 cells were injected into the NOD/SCID mice, we observed a higher tumor incidence with 100 CD44 þ cells than with CD44
À cells (i.e. 67 vs 7%; Table 1 ). No difference in tumor incidence was observed when higher numbers of cells were injected (Table 1) . Nevertheless, the CD44 À LAPC-4 cells needed longer latency periods to initiate tumors (Table 1) . Tumors derived from both CD44 þ and CD44 À LAPC-4 cells histologically resembled the unsorted LAPC-4 tumors ( Figure S3A) . Interestingly, the CD44 þ ( Figure S3Af ) but not CD44 À ( Figure S3Ai ) LAPC-4 tumors were often observed to invade the peritoneal muscle wall, suggesting that CD44 þ LAPC-4 cells are more invasive than CD44 À LAPC-4 cells. We similarly purified the CD44 þ and CD44 À LAPC-9 tumor cells to near homogeneity and carried out tumor experiments. The unsorted LAPC-9 tumor cells showed a cell number-dependent increase in tumorigenicity with a corresponding decrease in latency (Table 1) . Like LAPC4 tumors, we observed a significant difference in tumorigenicity between the CD44 þ and CD44 À cells when 100 cells were injected (100 vs 0%; Table 1 ). We even observed one tumor development with 10 CD44 c The time (in days) from tumor cell injection to when tumors were observed. The ranges are shown with the median tumor latencies shown in the parentheses.
d At necropsy, urogenital organs as well as multiple distant organs were examined for tumor dissemination (see Materials and methods for details).
þ cell population enriched in prostate tumor progenitors L Patrawala et al LAPC-9 cells injected (Table 1) . However, no difference in tumor incidence was observed when X1000 CD44 þ or CD44 À LAPC9 cells were injected although the CD44 À LAPC-9 cells developed tumors with slightly longer latencies (Table 1) . Tumors derived from both CD44 þ and CD44 À LAPC-9 cells histologically resembled the unsorted LAPC-9 tumors ( Figure S3B ). Similar to the CD44 þ LAPC-4 tumors, the CD44 þ ( Figure  S3Be , f) but not CD44 À ( Figure S3Bi ) LAPC-9 tumors often invaded the peritoneal muscle wall, suggesting that the CD44 þ LAPC-9 PCa cells are also more invasive than the CD44 À LAPC-9 cells.
þ PCa cells are more tumorigenic and metastatic than the CD44 À PCa cells when implanted orthotopically into the prostate To further study the tumorigenic potentials of CD44 þ and CD44
À PCa cells, we carried out surgical orthotopic implantation (SOI) experiments by implanting either unsorted or sorted cells acutely purified from the LAPC-9 xenograft tumors into NOD/SCID mice. As shown in Table 2 , the unsorted LAPC-9 cells demonstrated an increasing tumorigenicity related to the cell numbers injected. Interestingly, more tumor cells were needed to initiate the SOI tumors than subcutaneous tumors. For example, 100 LAPC-9 cells injected s.c. gave rise to tumors in 50% injections, whereas 10 000 LAPC-9 cells were required to achieve 50% tumor take when injected intraprostatically (compare Tables 1 and 2 ). Significantly, when 1000 CD44 þ LAPC-9 cells were injected into the prostate, we observed a 25% tumor take, whereas no tumor development was observed (within 7-12 months) with either unsorted or CD44 À LAPC-9 cells (Table 2 ). In fact, there was no tumor development with even 10 000 CD44 À LAPC-9 cells injected (Table 2) . Tumors were observed only with X100 000 CD44 À LAPC-9 cells injected (Table 2) . These results suggest 
þ cell population enriched in prostate tumor progenitors L Patrawala et al that the CD44 þ LAPC-9 cells are B100 times more tumorigenic than the CD44 À cells. Importantly, with B20 orthotopic tumors derived from unsorted or CD44 À cells, we did not observe a single metastasis (Table 2) . By contrast, we observed two metastases out of six (B33%) orthotopic tumors derived from the CD44 þ LAPC-9 cells (Table 2) . Tumors invaded into various lobes of mouse prostates (Figure 3b -e) as well as disseminated into several distant organs including the lymph node, bladder, spleen, lung, liver, and kidney (Figure 3f-l) . No metastasis to other organs (including bone) was observed in these two tumors. Together with the subcutaneous tumor experiments, these observations suggest that the CD44 þ PCa cells are more aggressive, invasive, and metastatic than the isogenic CD44 À PCa cells.
þ PCa cells possess some intrinsic properties of progenitor cells and can generate CD44 À PCa cells in vivo and in vitro We then asked whether the CD44 þ PCa cells might possess certain intrinsic biological properties that would endow them with higher tumorigenic and metastatic abilities. We first carried out BrdU pulse-chase experiments on LAPC-4 spheres as the long-term label-retaining cells (LRCs) have been shown to mark various stem/progenitor cell populations (Tumbar et al., 2004) . When pulsed for 2-48 h followed by a chase period of 0-5 days, B20-28% of the cells in the LAPC-4 spheres retained BrdU (Figure 4Aa ; Figure S4A ). The percentages of the LRCs began to decline with a 10-day chase and further decreased to 1-5% with 25-33 day chases (Figure 4Aa ; Figure S4A ). When the LAPC-4 spheres were double-stained for CD44 and BrdU, we observed only a very small percentage of cells showing CD44 and BrdU colocalization in spheres that had been BrdU-pulsed for 2-48 h without any chase or pulsed for 48 h and chased for up to 5 days (Figure 4Ab) . However, the percentages of CD44 and BrdU-colocalized cells significantly increased in spheres that had been BrdUpulsed for 48 h and chased for 10 days ( Figure S4B ; arrows), peaked in spheres chased for 25 days, and then declined in spheres chased for 33 days (Figure 4Ab ). These results suggest that the CD44 Table S2 for primer information. Figure 4B ). The CD44 þ LAPC9 cells also expressed higher levels of Oct-3/4 mRNA than the CD44 À LAPC-9 cells ( Figure 4B ). Higher levels of Oct-3/4, Bmi, and b-catenin mRNAs were also observed in the CD44 þ Du145 cells purified from the cultured cells (not shown). In contrast, similar levels of Notch-1 expression were observed in CD44 þ and CD44 À PCa cells ( Figure 4B) .
We then carried out in vivo and in vitro 'self-renewal' experiments to determine whether the CD44 Figure S5 ). For example, the LAPC-4 tumors contained B1% CD44 þ tumor cells (Table 3 ; Figure S5Aa- 
c). Tumors derived from the injected CD44
þ LAPC-4 cells contained 1-3% CD44 þ cells (Table 3 ; Figure S5Ad-f) . Similarly, the LAPC-9 tumors contained 14-20% CD44 þ tumor cells and CD44 expression was often patchy and heterogeneous (Table 3 ; Figure S5Ba -c). Tumors derived from purified CD44 þ LAPC-9 cells contained 10-20% bright CD44 þ cells (Table 3 ; Figure S5Bd -f). These results suggest that the CD44 þ PCa cells can generate CD44 À tumor cells in vivo. Similar results were obtained using the SOI tumors (not shown).
To confirm the ability of the CD44 þ PCa cells to generate CD44
À cells, we carried out in vitro clonal analysis using the CD44 þ and CD44 À Du145 cells purified from the xenograft tumors ( Figure 5 ). We observed that the CD44 þ cells, which were >99.5% pure in these experiments (e.g. Figure 5Ec ; the arrow indicates one of the two cells negative for CD44 among the 3000 cells plated; 99.9% purity), gave rise to CD44 À cells in a time-dependent manner ( Figure 5A and E). Quantitative clonal analyses ( Figure 5C ) revealed that in culture, the CD44 þ clones (illustrated in Figure 5Ed ) gradually decreased with a corresponding increase in the number of CD44 À clones (illustrated in Figure 5Ef , arrows), whereas the CD44 þ /CD44 À mixed clones (illustrated in Figure 5Ee ) remained relatively constant. Interestingly, we observed that B1% of the clonally plated CD44
þ cells appeared to undergo asymmetric cell division as CD44 was detected in only one of the two daughter cells (Figure 6a ). (Tables 1 and  2 ). Interestingly, tumors derived from the CD44 À PCa cells also contained CD44 þ cells (Table 3 ; Figure S5Ag i and Bg-i). Overall, the percentages of CD44 þ cells in the tumors derived from the injected CD44 À PCa cells resembled those in the unsorted tumors (Table 3 ). The exception was the percentages of the CD44 þ cells in the LAPC-9 tumors derived from the purified CD44 À LAPC-9 cells, which were generally lower than in the unsorted tumors or tumors derived from the CD44 þ LAPC-9 cells (Table 3; Figure S5Bg-i) . Because the purities of our CD44 À PCa cell populations are generally 98-100%, it is possible that the minor subsets of CD44 þ cells in the CD44
À cell-derived LAPC-4 (and LAPC-9) (Table 3 ). Another possibility is that a minor subset of cells in the CD44 À population might have the ability to develop into CD44 þ cells. To test this latter possibility, we similarly carried out clonal analysis. The results indeed revealed that some CD44 À Du145 cells (100% purity in these experiments; Figure 5Fa-c; no CD44 þ cells were observed in the 3000 cells plated) could give rise to CD44 þ cells in culture ( Figure  5B , D, and Fd-f). Interestingly, within the 9-day experimental period, we observed that the majority of the CD44 þ clones derived from the CD44 À cells were homogeneous CD44
þ clones (illustrated in Figure 5Ff , arrow) with a very few mixed clones ( Figure 5D ).
Discussion
The controversial involvement of CD44 in PCa development and progression (see Introduction) prompted us to prospectively and acutely purify the CD44 þ and CD44 þ LAPC-9 cells injected orthotopically can initiate tumor development, whereas X100 000 CD44 À cells are needed to establish tumor development, suggesting that the CD44
þ PCa cell population overall is B100 times more tumorigenic than the CD44 À population. It is presently unclear why more unsorted cells are required to initiate tumors in mouse prostates than at subcutaneous sites but the SOI tumor development data (Table 2 ) are probably more representative of human PCa development than the subcutaneous tumors (Table 1) .
Importantly, the CD44 þ PCa cells are more metastatic than the isogenic CD44
À cells -two of the six CD44 þ cell-derived tumors metastasized to multiple distant organs whereas none of B20 CD44 À PCa cellderived tumors disseminated. The subcutaneous prostate tumors derived from CD44
þ PCa cells are also much more invasive than the CD44 À cell-derived tumors. It is unclear whether the CD44 þ PCa cells have utilized CD44, which mediates cell adhesion to multiple substrates including proteoglycans and E-cadherin and also possesses various signaling functions, for their muscle and intraprostate invasion and distant dissemination. This possibility certainly exists considering that CD44 has previously been implicated in facilitating PCa cell invasion in vitro (e.g. Lokeshwar et al., 1995; Draffin et al., 2004; Omara-Opyene et al., 2004) . In this regard, it is of interest to note that the LAPC-9 tumors, which were initially isolated from a bony metastasis, contain many more CD44 þ cells than LAPC-4 tumors, which were originally isolated from a lymph node metastasis.
On the other hand, CD44 þ PCa cells, or a subset of cells in the CD44 PCa cells acutely purified from xenograft tumors express higher mRNA levels of several 'stemness' genes, including Oct-3/4, Bmi, b-catenin, and SMO. Oct-3/4 is a transcription factor critical for the self-renewal of teratocarcinoma cells and embryonic SCs (Chambers and Smith, 2004) and is also expressed in some stem-like cancer cells (Tai et al., 2005) . Bmi plays an essential role in determining the self-renewal and long-term proliferative capacity of not only normal hematopoietic and þ PCa cells also preferentially express b-catenin, one of the major mediators of the Wnt signaling pathway, and SMO, the activating receptor in the Hedgehog signaling pathway. Abnormal activation of both Wnt and Hedgehog signaling pathways has recently been implicated in PCa development and progression (Beachy et al., 2004; Yardy and Brewster, 2005) . It is conceivable that the preferential expression of Oct-3/4, Bmi, b-catenin, and SMO in the CD44
þ PCa cell population will endow some cells with certain stem/ progenitor cell properties. Third, the CD44 þ PCa cells can generate CD44
À tumor cells both in vitro and in vivo. The CD44
þ PCa cells in all of our experiments are highly purified (X98%). The LAPC-4 (or LAPC-9) tumors derived from as few as 100-1000 CD44 þ cells contain only a minor percentage of CD44 þ cells with the majority of tumor cells being CD44 (Maitland et al., 2005) . The CD44 þ /a2b1 lo /CD133 À population of cells purified from patient tumors is also tumorigenic when higher numbers of tumor cells are injected (Maitland et al., 2005) . Consistent with these observations, we find that B80% of our purified CD44
þ PCa cells are of the
À tumor progenitor phenotype (Patrawala et al., unpublished observations) . Our work (this study; Patrawala et al., 2005) and others' (Maitland et al., 2005) , together, suggest that solid tumors such as PCa will likely contain multiple populations of tumorigenic cells, all of which will be able to give rise to tumors but with different efficiencies.
We have recently shown that the LAPC-9 tumors have B0.1% SP, which is about 1000 times more tumorigenic than the non-SP cells (Patrawala et al., 2005) . In contrast, the highly purified ABCG2 þ (which mediates the SP phenotype in some cell types) PCa cell population has very similar tumorigenic potentials to the ABCG2 À cells (Patrawala et al., 2005) . These observations suggest that the SP might contain more primitive tumorigenic cells than the CD44 þ PCa cell population, which in turn contains more primitive tumorigenic cells than the ABCG2 þ PCa cells. On the other hand, the CD44 þ PCa cells likely represent a heterogeneous population of tumor progenitors with a minor subset of cells being more primitive and able to undergo asymmetric division. It will be interesting to further characterize the tumorigenic subpopulations in the CD44
þ PCa cells and also to compare these subpopulations with the SP with respect to their biological properties, tumorigenicities, and metastatic potentials. Such work is under way in our lab using both xenografts as well as primary PCa patient samples.
Materials and methods
Cells, reagents, and animals PPC-1, Du145, LNCaP, and PC3 (prostate); T47D, MCF-7, MDA-MB231, MDA-MB435, and MDA-MB468 (breast); COLO 320, DLD-1, RKO, and HCT116 (colon); RT4, UC14, UC1, and UC3 (bladder); D54, U87, U251, and U373 (glioma); WM266-4 and WM562-4 (melanoma), Hela (cervical), and SKOV-3 (ovarian) cancer cells were obtained from ATCC or collaborators and cultured in the recommended media containing 5-10% of heat-inactivated FBS. The NHP6-hTERT/T and NHP6-DNp53/T cells were established in our were courtesy of C Sawyers (Reiter and Sawyers, 2001 ) and maintained in NOD/SCID mice. Du145 xenograft tumors were established using early-passage cells and maintained in NOD/SCID mice. All animals were obtained from Jackson Laboratories and maintained in standard conditions according to the Institutional guidelines. Antibodies used include Ber-EP4 (mAb; Dako), CD31 (mAb; BD PharMingen), CK5 (pAb; BabCO), caspase-3 (mAb; BD PharMingen), CK18 (mAb; BD PharMingen), BrdU (mAb), and PSA and AR (mAbs; Santa Cruz). The mouse monoclonal anti-human CD44 antibody and the FITC-conjugated anti-CD44 antibody were obtained from BD PharMingen. The isotype control antibody and FITC, PE, or AlexaFluor-conjugated secondary antibodies were from Chemicon. All chemicals were obtained from Sigma unless specified otherwise.
Indirect immunofluorescence, flow cytometry analysis of CD44 expression, and FACS of CD44 þ and CD44 À cells Fluorescence microscopy was carried out as previously described (Bhatia et al., 2005; Patrawala et al., 2005) . For flow cytometry, cells were dissociated with Accutase (Innovative Cell Tech Inc., San Diego, CA, USA) and washed (2 Â ) in a serum-free medium. Cells were stained live in the staining solution containing BSA and FITC-conjugated monoclonal anti-CD44 (15 min at 41C). Samples were analysed on a Coulter Epics Elite flow cytometor. A minimum of 500 000 viable cells was measured per sample. For FACS, 2-5 Â 10 7 cells were similarly stained for CD44 and used to sort out CD44 þ and CD44 À cells. For the positive population, only the top 10% most brightly stained cells were selected. For the negative population, only the bottom 5% most dimly stained cells were selected.
Clonal analysis and clonogenic assays
Tumor cells were plated at clonal density, that is, 100-1000 cells per coverslip or T25 slide flask. Clones with >50 cells were scored within 1-2 weeks. The percentage of cells that initiated a clone was presented as cloning efficiency. In some experiments, the numbers of cells in individual clones were counted. Alternatively, the total numbers of cells in each condition were determined. For clonogenic assays, cells were plated at 1000-2000 cells/well in six-well culture dishes coated with a thin layer of 1% solidified agar. Spheres or spheroids that arose within 1-2 weeks were presented as clonogenicity (%). Triplicate samples were run for each cell type and at least two individuals scored the clones and spheres separately in a blind fashion.
Xenograft tumor processing and in vivo tumorigenicity experiments Basic procedures were previously described (Bhatia et al., 2003; Patrawala et al., 2005) . Briefly, xenograft prostate tumors (NHP6-DNp53/T, Du145, LAPC-4, and LAPC-9) were aseptically dissected out from animals and minced into B1 mm 3 pieces in DMEM supplemented with 10% FBS. After rinsing in the same medium (2 Â ), tumor tissues were incubated with 1 Â Accumax (1200-2000 U/ml proteolytic activity containing collagenase and DNase; Innovative Cell Technologies, Inc., San Diego, CA, USA) at 10 ml/1 g tissue in DPBS for 20 min at 371C under rotating conditions. Single-cell suspension was obtained by filtering the supernatant through a 40-mm cell strainer and cell suspension was then gently loaded onto a layer of Histopaque-1077 gradient and then centrifuged at 400 g for 30 min at room temperature. Red blood cells, dead cells, and debris were removed from the bottom of the tube and live nucleated cells collected at the interface. The resultant cell mixture was depleted of lineage-positive host cells using the MACS Lineage Cell Depletion Kit (Miltenyi Biotec, Auburn, CA, USA). Briefly, cells were first incubated (10 min at 41C) in the staining solution (PBS, pH 7.2, 0.5% FBS, 0.5 mg/ml insulin) containing biotinylated antibodies against a panel of lineage antigens (CD5, CD45R, CD11b, anti-Ly-6G, 7-4, and Ter-119). Cells were then incubated with the antibiotin Microbeads (15 min at 41C) and the Lin À cells were eluted using the MS columns. The eluted prostate cancer cells were all human epithelial cells as confirmed by their expression of Ber-EP4, a surface marker unique to human epithelial cells. Purified cells were used in various experiments including FACS, sphere formation assays, and tumor development experiments.
For subcutaneous tumor development experiments, cells were injected in 40-ml of medium:Matrigel (1:1) s.c. into NOD/ SCID mice (6-8 weeks old). For SOI experiments, animals were anesthetized and cells were injected in 25-ml medium into the dorsal prostate. Tumor development was monitored 2 weeks after surgical implantation. When tumor burden became obvious, the experiment was terminated, animals were killed, and primary tumors together with the urogenital (UG) organs except bladder dissected out. Tumor weights (with UG organs) were determined and prostates, together with several other tissues/organs (i.e. lymph nodes, lung, brain, bone, intestine, colon, pancreas, stomach, liver, femur, and tibia) were used in H-E staining and immunohistochemical analysis (Bhatia et al., 2003) . Those animals injected with tumor cells but with no sign of tumor burden were generally terminated in 6-7 months after tumor cell inoculation and animals were opened up in the injection sites to confirm that there was no tumor development.
Sphere formation assays, sphere cryosection staining, and BrdU pulse chase to identify LRC Various numbers of purified LAPC-4 cells were directly plated in IMDM medium plus 20% FBS. Distinct spheres started to form within 1-2 weeks after plating. For LAPC-9 sphere formation assays, cells were plated in the same medium but on a layer of mitomycin C-treated Swiss 3T3 fibroblast feeder layer. To determine the sphere growth kinetics, 50-100 spheres were harvested on a weekly basis and the average number of live cells per sphere was determined upon dissociation. Spheres were also harvested and embedded in either OCT or paraffin and serial sections (5-8 mm) were made and stained for various markers (CD44, CK5, CK18, AR, Ber-EP4, caspase-3, etc.) . In some experiments, spheres were briefly (2 h) incubated with BrdU (2.5 mM) and sections were processed for BrdU staining. To identify and characterize LRC in tumor spheres, spheres were first pulsed with BrdU for 2, 3, or 7 days. Then, BrdU was removed by changing medium and the spheres were 'chased' for different periods of time. At the end of each time point, spheres were harvested and embedded in OCT. Serial cryosections (8 mm) were double-stained for BrdU and CD44 and then counterstained by DAPI. On average, 4-8 sections were observed and 1000-2000 cells were quantified for BrdU þ / CD44 þ or single-positive cells.
'Self-renewal' experiments Purified CD44 þ and CD44 À cancer cells were plated at clonal density, that is, 100 cells/18 mm 2 glass coverslip. Cells were cultured for different time periods for up to 2 weeks. The percentage of cells that initiated a clone was presented as cloning efficiency and the clone sizes were determined for some time points. Finally, coverslips were stained for CD44
CD44
þ cell population enriched in prostate tumor progenitors L Patrawala et al expression. Triplicate samples were run for each cell type and experiments repeated when feasible. For in vivo self-renewal experiments, tumor cells from the unsorted or CD44-sorted tumors were freshly purified as described above, stained for CD44, and used to quantify the CD44-expressing cells by flow cytometry.
RT-PCR analysis
Total RNA was isolated using the Absolutely RNA Nanoprep Kit (Stratagene) and used in semiquantitative RT-PCR analysis (Patrawala et al., 2005) , using primers listed in Table S2 .
